Reckitt Benckiser Group plc (OTCMKTS:RBGLY – Get Free Report) has been assigned an average rating of “Buy” from the eight ratings firms that are presently covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and three have given a strong buy recommendation to the company.
A number of equities research analysts have recently weighed in on RBGLY shares. Royal Bank of Canada restated an “outperform” rating on shares of Reckitt Benckiser Group in a report on Friday, March 7th. HSBC upgraded Reckitt Benckiser Group from a “hold” rating to a “buy” rating in a research note on Wednesday, December 11th. Hsbc Global Res raised Reckitt Benckiser Group from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, December 11th. Finally, Barclays lowered Reckitt Benckiser Group from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, February 4th.
Check Out Our Latest Analysis on Reckitt Benckiser Group
Reckitt Benckiser Group Stock Performance
Reckitt Benckiser Group Increases Dividend
The company also recently disclosed a dividend, which will be paid on Thursday, June 5th. Shareholders of record on Friday, April 11th will be issued a dividend of $0.2909 per share. This is a positive change from Reckitt Benckiser Group’s previous dividend of $0.19. The ex-dividend date of this dividend is Friday, April 11th.
About Reckitt Benckiser Group
Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; brain health products; migraine-headaches and rheumatic pain products; sore throat medications; and hair removal products under the Airborne, Clearasil, Dettol, Durex, Gaviscon, Move Free, Neuriva, Nurofen, Mucinex, Strepsils, and Veet brands.
See Also
- Five stocks we like better than Reckitt Benckiser Group
- How to Invest in Small Cap StocksĀ
- AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market
- Stock Splits, Do They Really Impact Investors?
- 3 ETFs to Ride the VIX Surge During Market Volatility
- Why Are Stock Sectors Important to Successful Investing?
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with MarketBeat.com's FREE daily email newsletter.